Neferine inhibits angiotensin II-induced rat aortic smooth muscle cell proliferation predominantly by downregulating fractalkine gene expression

LULU ZHENG¹, YONGWEN CAO¹, SHAO LIU², ZHENYU PENG³ and SAIDAN ZHANG¹

Departments of ¹Cardiology and ²Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008; ³Department of Emergency, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China

Received January 11, 2014; Accepted June 19, 2014

DOI: 10.3892/etm.2014.1952

Abstract. Neferine inhibits the angiotensin II (AngII)-induced proliferation of vascular smooth muscle cells (SMCs), but the underlying mechanism is unclear. The aim of this study was to explore the mechanism underlying the effect of neferine on the proliferation of vascular SMCs. Rat aortic SMCs (RASMCs) were used and fractalkine (Fkn) gene expression was measured by quantitative polymerase chain reaction and western blot analysis. The proliferation of RASMCs was analyzed by MTT assay and flow cytometry. It was revealed that AngII induced Fkn expression in a dose- and time-dependent manner. Fkn-knockdown with small interfering RNA attenuated the AngII-induced RASMC proliferation. Furthermore, neferine inhibited Fkn expression and attenuated the AngII-induced RASMC proliferation. These findings suggest that the Fkn gene may play an important role in AngII-induced RASMC proliferation and that neferine acts to attenuate AngII-induced RASMC proliferation by inhibiting Fkn expression.

Introduction

The proliferation of smooth muscle cells (SMCs) plays a pivotal role in cardiovascular diseases (1-3). However, the underlying mechanism remains unclear. The renin-angiotensin-aldosterone system (RAAS) is involved in endothelial dysfunction, vascular remodeling, oxidative stress, proinflammatory cytokine production and adhesion molecule synthesis in the vascular wall (4). As an important part of the RAAS, angiotensin II (AngII) is able to stimulate the growth and proliferation of vascular SMCs by binding to the AngII receptor Type 1. AngII activates downstream signaling molecules, such as protein kinase C and mitogen-activated protein kinase (MAPK), and a number of extracellular signaling molecules, including extracellular signal-regulated kinase (ERK) 1/2, p38MAPK, c-Jun N-terminal kinase and ERK5, to carry out its functions (5-8).

Chemokines are low molecular-mass cytokines that, based on the spacing of N-terminal cysteine residues, are classified into the C, CC, CXC and CX3C families; fractalkine (Fkn; CX3CL1) is the only member of the CX3C family identified to date (9). Studies have shown that Fkn is involved in various inflammatory diseases, including cardiovascular diseases (10-12). Sullivan et al (13) found that the expression of Fkn was markedly increased in the mesenteric arteries of spontaneously hypertensive rats (SHRs) and was notably higher in female SHRs. Studies have also demonstrated that Fkn can induce SMC proliferation, which is mediated by nuclear factor κB-dependent inflammatory signals (14,15). Recently, Rius et al (16) found that by stimulating endothelial cells with 1 µmol/l AngII, Fkn expression was upregulated in the cells. These findings highlight the significance of Fkn in the pathogenesis of hypertension and suggest it may play a role in vascular remodeling.

Neferine is extracted from the herb Nelumbo nucifera (Gaertn.), an ingredient in Traditional Chinese Medicine. Studies have shown that N. nucifera has multiple biological activities, including attenuating bleomycin-induced pulmonary fibrosis (17), enhancing insulin sensitivity in insulin-resistant rats (18) and exerting an antioxidant effect against isoproterenol-induced oxidative stress (19). Previous studies have found that N. nucifera leaf extract and neferine can inhibit the proliferation of vascular SMCs; however the underlying mechanism has yet to be elucidated (20,21).

Based on these previous findings on the role of Fkn in the pathogenesis of various cardiovascular diseases, on the proliferative effects of AngII on vascular SMCs and on the effects of N. nucifera and neferine, we hypothesized that Fkn could be involved in the AngII-induced proliferation of vascular SMCs, and that the anti-proliferative effects of neferine on the cells could be fundamentally associated with Fkn and AngII. The aim of the present study was to explore the mechanisms underlying the effects of AngII and neferine on rat aortic smooth muscle cells (RASMCs).

Correspondence to: Professor Saidan Zhang, Department of Cardiology, Xiangya Hospital, Central South University, 88 Xiangya Road, Changsha, Hunan 410008, P.R. China
E-mail: zhangsaidan_123@126.com

Key words: neferine, angiotensin II, fractalkine, rat aortic smooth muscle cells, proliferation
Materials and methods

Materials. The RASMC line was obtained from the American Type Culture Collection (Manassas, VA, USA). The AngII, propidium iodide (PI) solution, bichinonic acid (BCA) protein assay and RNase A were purchased from Sigma (St. Louis, MO, USA). Goat polyclonal anti-Fkn antibody and mouse monoclonal anti-β-actin antibody were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Neferine, with a purity of 98.6%, was extracted from the seed embryo of N. nucifera using a preparative high-speed counter-current chromatography method by the Department of Pharmacy, Xiangya Hospital (Central South University, Changsha, China) (22).

Cell culture and experimental design. The cells were grown in Dulbecco's Modified Eagle's Medium (DMEM; Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone) at 37 °C in a humidified atmosphere of 5% CO₂. Cells between four and seven passages were used for all the experiments in this study. RASMCs were seeded on 96-well plates (0.2-1.0x10⁴ cells/well) or six-well culture plates (1x10⁵ cells/well) and cultured for 24 h, prior to being starved for 24 h in DMEM containing 0.1% FBS. Different concentrations of AngII (1x10⁻⁶, 1x10⁻⁷ and 1x10⁻⁸ M) were then added and the cells were cultured for a certain time-period according to the experimental design (6, 12 or 24 h) to evaluate the effects of AngII on RASMC proliferation and Fkn expression.

To examine the effect and determine a suitable concentration of neferine on the proliferation of RASMCs, the cells were divided into four groups: Control and neferine treatment with three different concentrations of neferine (1, 5 and 10 µmol/l obtained by dilution with DMEM). The cells were then cultured for another 24 h prior to an MTT assay being performed. In order to conduct all the other experiments in the neferine study, the cells that had reached synchronization were divided into three groups: Control, AngII (1x10⁻⁶ M) and neferine plus AngII (neferine at 5 µmol/l, preculture for 1 h and the subsequent addition of AngII at 1x10⁻⁶ M). The cells were cultured for a further 24 h prior to undergoing analyses, including MTT assay, flow cytometry, western blotting and the quantitative polymerase chain reaction (qPCR). For RNA interference and cell transfection, the cells were divided into four groups: Control, AngII (1x10⁻⁶ M), control small interfering (si)RNA (following transfection with control siRNA, AngII at 1x10⁻⁶ M was added) and Fkn siRNA plus AngII (following transfection with Fkn siRNA, AngII at 1x10⁻⁶ M was added). The cells were subsequently cultured for 24 h for the MTT assay and flow cytometry. All the experiments were performed in triplicate. The study was approved by the Ethics Committee of Xiangya Hospital.

MTT assay. Subsequent to finishing the cell culture according to the experimental design, 20 µl MTT (5 mg/ml) solution was added and incubated for 4 h. The supernatants of the cell culture were then removed and 150 µl dimethylsulfoxide was added to each well. A multi-well plate reader (Model Stat-Fax-2100, Awareness Technology Inc., Palm City, FL, USA) was subsequently used to determine the optical density (OD). The absorbance of samples was measured at 570 nm (OD₅₇₀), and the absorbance at 690 nm was used as a reference. The background absorbance of the medium was also subtracted. Each assay was repeated in triplicate, and the mean for each experiment was calculated.

Flow cytometric determination of cell cycles. At the end of cell culturing, the cells were trypsinized and washed twice with cold phosphate-buffered saline (PBS). The cells were then fixed with ice-cold 70% ethanol at 4 °C overnight. The cells were subsequently centrifuged to remove fixative solution and washed with PBS twice, and then stained with 50 µg/ml PI solution and RNase for 30 min in the dark. A total of ≥10,000 cells were analyzed. The percentages of cells in different phases of the cell cycle were measured with a fluorescence-activated cell sorting flow cytometer (Cytomics™ FC 500; Beckman Coulter, Miami, FL, USA) and analyzed with CXP software (Beckman Coulter). The percentage of cells in the S and G2/M phases was used as the indicator for cell proliferation.

RNA interference and cell transfection. To confirm the role of Fkn in the AngII-induced proliferation of RASMCs, Fkn siRNA was developed to silence Fkn gene expression, as Fkn expression has been found in RASMCs under certain stimuli (23,24). The Fkn siRNA (sense strand, 5'-GCU GUGGUAGUAUUCAUAAdTdT-3' and antisense strand, 3'-dTdTTCGACACCAUAUAUGAU-5') was synthesized by RayBiotech (Guangzhou, China) and was transfected into RASMCs using Lipofectamine® 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Transfection efficiency was determined by qPCR and western blot analysis.

Western blot analysis. The cells were harvested at the end of culture and the proteins were obtained by use of radioimmunoprecipitation assay buffer containing 1 mM phenylmethylsulfonyl fluoride. The protein concentrations were measured using a BCA protein assay. Subsequent to being boiled in 100°C water for 5 min, equal amounts of total protein were separated by 8% SDS-PAGE. The protein was then transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% evaporated skimmed milk containing 0.1% Tween 20 for 2 h and then incubated with primary antibodies at 4°C overnight. The membranes were subsequently washed with Tris-buffered saline with Tween 20 (TBST) four times, followed by incubation with horseradish peroxidase-conjugated secondary antibodies for 1-2 h at room temperature. Following washing with TBST, the target protein bands were detected using an enhanced chemiluminescence detection kit with a ChemiDOC™ MP imaging system (Bio-Rad, Hercules, CA, USA).

qPCR. Total RNA was extracted from the cells at the end of culture using TRIzol® (Invitrogen Life Technologies). The primers of Fkn and GAPDH were designed by Beijing Sunbiotech Co., Ltd. (Beijing, China). The reverse transcription reaction was performed with 5 ng total RNA. For PCR amplification, cDNAs were amplified using SYBR Green qPCR Mix (Takara, Dalian, China); PCR protocols are summarized in Table I. The amplification reaction for each
sample was performed in triplicate. Results are expressed as the ratio of Fkn to GAPDH mRNA.

**Statistical analysis.** SPSS 16.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis. All data are expressed as the mean ± standard deviation and were analyzed using the Student’s t-test for two group comparisons or analysis of variance followed by the Student-Newman-Keuls test for multiple groups. P<0.05 was considered significant.

### Results

AngII promotes RASMC proliferation and Fkn gene expression. MTT assay showed that AngII could promote RASMC proliferation in a time- and concentration-dependent manner (P<0.05; Fig. 1A). Accompanied by the enhanced proliferation of RASMCs, Fkn protein expression, as shown by western blot analysis, was significantly upregulated following the use of AngII, and the overexpression was also in a concentration- and...
ZHENG et al: NEFERINE INHIBITS Ang II-INDUCED RASMC PROLIFERATION THROUGH FRACTALKINE

Fkn expression in RASMCs

WB analysis

qPCR

MTT assay

Cell cycle

Figure 2. Effect of Fkn gene-knockdown on AngII (1x10^{-6} M)-induced proliferation of RASMCs. (A) Fkn siRNA inhibited Fkn expression at both mRNA and protein levels in RASMCs stimulated by AngII, while control siRNA showed no effects on AngII-treated RASMCs. (B) MTT assay and (C) Cell cycle analysis by flow cytometry showed that Fkn-knockdown also attenuated the AngII-induced cell proliferation. *P<0.05 vs. control; +P<0.05 vs. AngII. Fkn, fractalkine; RASMCs, rat aortic smooth muscle cells; WB, western blot; AngII, angiotensin II; qPCR, quantitative polymerase chain reaction; OD, optical density; siRNA, small interfering RNA.

time-dependent manner (P<0.05; Fig. 1B). By contrast, control cells only showed a baseline Fkn expression.

Fkn gene silencing suppresses AngII-induced RASMC proliferation. Following Fkn siRNA transfection, the Fkn expression at the mRNA and protein levels in the AngII-stimulated Fkn siRNA group was suppressed in comparison with that in the AngII-stimulated control siRNA group (P<0.05; Fig. 2A). Furthermore, MTT assay and flow cytometry demonstrated that the Fkn siRNA transfection significantly attenuated the AngII-induced cell proliferation (P<0.05; Fig. 2B and C).

Neferine inhibits the proliferation of both normal and AngII-stimulated RASMCs. MTT assay showed that neferine inhibited RASMC proliferation in a concentration-dependent manner in comparison with the control group (P<0.05). Neferine treatment at a concentration of 5 µmol/l appeared to result in moderate inhibition, and this concentration of neferine was used in the following experiments (Fig. 3A). MTT assay also showed that 5 µmol/l neferine attenuated the proliferative effect of AngII at 1x10^{-6} M (neferine pretreatment for 1 h followed by AngII treatment) (P<0.05; Fig. 3B). This inhibitive effect of neferine on the AngII-induced proliferation of RASMCs was further confirmed by cell cycle analysis using flow cytometry (P<0.05; Fig. 3C).

Neferine attenuates AngII-induced Fkn expression in RASMCs. Fkn mRNA and protein expression in normal RASMCs was limited, but, following exposure to AngII for 24 h, Fkn expression was significantly upregulated (P<0.05). By contrast, pretreatment with neferine (5 µmol/l) markedly attenuated the enhanced Fkn expression at the mRNA and protein levels (P<0.05; Fig. 4A and B).

Discussion

In the present study, the following observations were noted: i) AngII stimulated Fkn expression in RASMCs; ii) Fkn gene-knockdown attenuated the AngII-induced proliferation of RASMCs and iii) neferine inhibited AngII-induced Fkn expression, attenuating the proliferative effect of AngII on RASMCs.
Accumulating evidence has shown that Fkn plays an important role in cardiovascular diseases (12,25,26). Fkn is an atypical chemokine that exists in either a membrane-bound form or as a soluble chemokine (9). The membrane-bound form acts as an adhesion molecule and enables leucocyte adhesion via binding to chemokine (C-X3-C motif) receptor 1 (CX3CR1), while the soluble form functions as a chemoattractant for monocytes and T cells (27). Fkn is expressed in atherosclerotic plaques (28,29), and an absence of Fkn or its receptor, CX3CR1, prevents atherosclerotic lesion formation (30,31).

The proliferation of SMCs is involved in atherosclerosis and hypertension, and AngII is an important stimulus among the numerous involved (7,32). AngII contributes to the vascular SMC growth, endothelial dysfunction and vascular inflammation in hypertension. There is little Fkn expression in endothelial cells or SMCs under normal conditions; however, overexpression of Fkn has been observed when cells are under a certain stimulation, such as interferon-γ and tumor necrosis factor-α (9,23). Although there has been a report of AngII inducing Fkn overexpression in endothelial cells (16), the effect of AngII on Fkn expression in SMCs has not been documented to date. In this study, it was revealed that AngII upregulated Fkn expression in a time- and concentration-dependent manner, and knockdown of Fkn caused a significant decrease in cell proliferation in AngII-stimulated RASMCs.

In this study, neferine was again found to be capable of inhibiting AngII-induced RASMC proliferation, which was consistent with a previous study (22), and the anti-proliferative effect of neferine on AngII-stimulated RASMCs was revealed to be the result of suppressed Fkn expression. Neferine markedly attenuated the proliferative effect of AngII on the RASMCs by suppressing Fkn gene expression.

Figure 4. Neferine attenuates the AngII (1x10⁻⁶ M)‑induced Fkn overexpression in RASMCs. (A) qPCR showed the mRNA expression levels under different experimental conditions; while control cells showed a baseline Fkn expression, AngII caused a significant overexpression of the Fkn gene. With neferine pretreatment, the overexpression of Fkn was greatly attenuated. (B) WB analysis showed a similar change in Fkn expression at the protein level among the experimental groups. *P<0.05 vs. control; †P<0.05 vs. AngII. qPCR, quantitative polymerase chain reaction; AngII, angiotensin II; Nef, neferine; WB, western blot; Fkn, fractalkine; RASMCs, rat aortic smooth muscle cells.

Accumulating evidence has shown that Fkn plays an important role in cardiovascular diseases (12,25,26). Fkn is an atypical chemokine that exists in either a membrane-bound form or as a soluble chemokine (9). The membrane-bound form acts as an adhesion molecule and enables leucocyte adhesion via binding to chemokine (C-X3-C motif) receptor 1 (CX3CR1), while the soluble form functions as a chemoattractant for monocytes and T cells (27). Fkn is expressed in atherosclerotic plaques (28,29), and an absence of Fkn or its receptor, CX3CR1, prevents atherosclerotic lesion formation (30,31).

The proliferation of SMCs is involved in atherosclerosis and hypertension, and AngII is an important stimulus among the numerous involved (7,32). AngII contributes to the vascular SMC growth, endothelial dysfunction and vascular inflammation in hypertension. There is little Fkn expression in endothelial cells or SMCs under normal conditions; however, overexpression of Fkn has been observed when cells are under a certain stimulation, such as interferon-γ and tumor necrosis factor-α (9,23). Although there has been a report of AngII inducing Fkn overexpression in endothelial cells (16), the effect of AngII on Fkn expression in SMCs has not been documented to date. In this study, it was revealed that AngII upregulated Fkn expression in a time- and concentration-dependent manner, and knockdown of Fkn caused a significant decrease in cell proliferation in AngII-stimulated RASMCs.

In this study, neferine was again found to be capable of inhibiting AngII-induced RASMC proliferation, which was consistent with a previous study (22), and the anti-proliferative effect of neferine on AngII-stimulated RASMCs was revealed to be the result of suppressed Fkn expression. Neferine markedly attenuated the proliferative effect of AngII on the RASMCs by suppressing Fkn gene expression.

In conclusion, the findings in this study show that the Fkn gene plays an important role in the AngII-induced proliferation of RASMCs. Through Fkn, AngII exerts its proliferative effect
on the cells, and by inhibiting Fkn expression, neferine exerts its anti-proliferative effects on the AngII-stimulated cells. Further studies are, however, required to fully understand the mechanisms and underlying signaling pathways of SMC proliferation.

Acknowledgements

This study was supported by a grant from the Hunan Provincial Science and Technology Department, China (no. 12JJ5070).

References

1. Viiri LE, Full LE, Nadin TJ, Bequem S, Didangelas A, Astola N, Berge RK, Seppälä I, Shahlooh J, Frankin JJ, Perretti M, Lehtimäki T, Davies AH, Wait R and Monaco C: Smooth muscle cells in human atherosclerosis: proteome profiling reveals differences in expression of Annexin A1 and mitochondrial proteins in carotid disease. J Mol Cell Cardiol 54: 65-72, 2013.

2. Savoia C, Burger D, Nishigaki N, Montezano A and Touyz RM: Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 13: e11, 2011.

3. Liu G, Himation H, Hosomi N, Lei P, Pelisch N, Nakano D, Kiyou moto H, Ma H and Nishiyama A: Mechanical stretch potentiates angiotensin II-induced proliferation in spontaneously hypertensive rat vascular smooth muscle cells. Hypertens Res 33: 1250-1257, 2010.

4. Kaval DR and Schiffrin EL: Angiotensin II, aldosterone, and anti-inflammatory lymphocytes: interplay and therapeutic opportunities. Int J Hypertens 2012: 829786, 2012.

5. Touyz RM and Schiffrin EL: Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672, 2000.

6. Eguchi S, Dempsy PJ, Frank GD, Motley ED and Inagami T: Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloproteinase-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276: 7957-7962, 2001.

7. Shi R, Hu C, Yuan Q, Yang T, Peng J, Li Y, Bai Y, Cao Z, Cheng G and Zhang G. Involvement of vascular peroxiredoxin 1 in angiotensin II-induced vascular smooth muscle cell proliferation. Cardiovasc Res 91: 27-36, 2011.

8. Zhao Y, Liu J, Li L, Liu L and Wu L: Role of Ras/PCKZeta/MEK/ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul Pept 128: 43-50, 2005.

9. Bazan GF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644, 1997.

10. Balabanian K, Foussat A, Dorfmueller P, Durand-Gassin E, Capel F, Bouchet-Delbos L, Portier A, Marafongo-Koka A, Kryzysie R, Rimaniol AC, Simonneau G, Emelie D and Humbert M: CX3(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 1419-1425, 2002.

11. Schäfer A, Schulz C, Fraccarollo D, Tess, P, Leutke M, Egenthaler M, Seidt S, Heider P, Ertl G, Massberg S and Baurerch J: The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 27: 55-62, 2007.

12. Xuan W, Liao Y, Chen B, Huang Q, Xu D, Liu Y, Bin J and Kitakaze M: Determinal effect of fractalkine on myocardial ischemia and heart failure. Cardiovasc Res 92: 385-393, 2011.

13. Sullivan JC, Par doit JC, Doran D, Zhang Y, She JX and Pollock JS: Greater fractalkine expression in mesenteric arteries of female spontaneously hypertensive rats compared with males. Am J Physiol Heart Circ Physiol 296: H1080-H1089, 2008.

14. Perros F, Dorfmueller P, Souza R, Durand-Gassin E, Godot V, Capel F, Adnot S, Eddahibi S, Mazmanian M, Fadel E, Herve P, Simonneau G, Emilie D and Humbert M: Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 29: 937-943, 2007.

15. Chandrasekar B, Mummidii S, Perlra RP, Bysani S, Dulin NO, Liu F and Melby PC: Fractalkine (CX3CCL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signal inducible muscle cell proliferation through an autocrine pathway. Biochem J 373: 547-558, 2003.

16. Rius C, Piqueras L, Gonzalez-Navarro H, Albertos F, Company C, Lopez-Ginés C, Ludwig A, Blanes JI, Morcillo EJ and Sanz MJ: Arterial and venous endothelia display differential functional fractalkine (CX3CCL1) expression by angio tensin-II. Arterioscler Thromb Vasc Biol 33: 96-104, 2013.

17. Zhao L, Wang X, Chang Q, Xu J, Huang Y, Guo Q, Zhang S, Wang W, Chen X and Wang J: Neferine, a bisbenzylisoquinoline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur J Pharmacol 627: 304-312, 2010.

18. Pan Y, Cai B, Wang K, Wang S, Zhou S, Yu X, Xu B and Chen L: Neferine enhances insulin sensitivity in insulin resistant rats. J Ethnopharmacol 124: 98-102, 2009.

19. Lalitha G, Poornima P, Archanah A and Padma VV: Protective effect of neferine against isoproterenol-induced cardiac toxicity. Cardiovasc Toxicol 13: 168-179, 2013.

20. Ho HH, Hsu LS, Chan KC, Chen HM, Wu CH and Wang CJ: Extract from the leaf of nucifera reduced the development of atherosclerosis via inhibition of vascular smooth muscle cell proliferation and migration. Food Chem Toxicol 48: 159-168, 2010.

21. Li XC, Tong GX, Zhang Y, Liu SX, Jin QH, Chen HH and Chen P: Neferine inhibits angiotensin II-stimulated proliferation in vascular smooth muscle cells through heme oxygenase-1. Acta Pharmacol Sin 31: 679-686, 2010.

22. Liu S, Wang B, Li XZ, Qi LF and Liang YZ: Preparative separation and purification of liensinine, isoliensinine and neferine from seed embryo of Nelumbo nucifera GAERTN using high-speed counter-current chromatography. J Sep Sci 32: 2476-2481, 2009.

23. Ludwig A, Berkhout T, Moores K, Groot P and Chapman G: Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 168: 604-612, 2002.

24. Lucas AD, Bursill C, Gazik TJ, Sadowski J, Channon KM and Greaves DR: Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CCL1). Circulation 108: 2498-2504, 2003.

25. Ikejima H, Imanishi T, Tsujioka H, Kashiwagi M, Kuroi A, Tanimoto T, Kitabata H, Ishibashi K, Komukai K, Takeshita T and Akasaka T: Uregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J 74: 337-345, 2010.

26. Flierl U and Schäfer A: Fractalkine - a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost 108: 457-462, 2007.

27. Inami T, Hishima K, Hara K, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ and Yoshide O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530, 1997.

28. Thombs JB, Boulanger A, Waehre T, Smith C, Sandberg WJ et al: Expression of fractalkine (CX3CCL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 25: 2567-2572, 2005.

29. Stollà M, Pelsko J, von Brühl ML, Schäfer A, Barocke V, Heider P, Lorenz M, Trimiceria A, Steinhart A, Bauersachs J, Bray PF, Massberg S and Schulz C: Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One 7: e43572, 2012.

30. Combadère C, Potteaux S, Gao JL, Esposito B, Casanova S et al: Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009-1016, 2003.

31. Lesnik P, Haskell CA and Charo IF: Decreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111: 333-340, 2003.

32. Cheng LF, Ni GH, Tang Y, Li L, Li YJ, Wang YJ, Wang CL, Yuan Q, Shi RZ, Hu CP and Yang TL: Involvement of profilin-1 in angiotensin II-induced vascular smooth muscle cell proliferation. Vascul Pharmacol 55: 34-41, 2011.